GSK plc (NYSE:GSK) Shares Acquired by Roble Belko & Company Inc

Roble Belko & Company Inc lifted its holdings in shares of GSK plc (NYSE:GSK) by 315.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,845 shares of the pharmaceutical company’s stock after buying an additional 2,160 shares during the period. Roble Belko & Company Inc’s holdings in GSK were worth $122,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Versant Capital Management Inc raised its holdings in GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 676 shares in the last quarter. BKM Wealth Management LLC bought a new stake in GSK during the fourth quarter worth approximately $32,000. Richardson Financial Services Inc. bought a new stake in GSK during the fourth quarter worth approximately $40,000. Jones Financial Companies Lllp increased its holdings in shares of GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after buying an additional 509 shares in the last quarter. Finally, Princeton Global Asset Management LLC raised its stake in GSK by 54.3% during the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock valued at $56,000 after purchasing an additional 533 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GSK has been the topic of several recent analyst reports. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research note on Thursday. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Finally, The Goldman Sachs Group initiated coverage on shares of GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.00.

GSK Stock Down 0.7 %

NYSE:GSK traded down $0.28 during trading hours on Friday, reaching $40.48. The company’s stock had a trading volume of 3,490,372 shares, compared to its average volume of 3,238,833. The company has a market cap of $83.89 billion, a price-to-earnings ratio of 14.67, a price-to-earnings-growth ratio of 1.23 and a beta of 0.66. GSK plc has a one year low of $33.67 and a one year high of $45.92. The business’s 50-day moving average is $42.55 and its 200-day moving average is $41.09. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The firm had revenue of $9.34 billion during the quarter, compared to analysts’ expectations of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. Equities research analysts predict that GSK plc will post 4.11 EPS for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.72%. GSK’s payout ratio is currently 53.26%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.